Adaptimmune Therapeutics Plc (ADAP): Charles Elliott Sigal , director of Adaptimmune Therapeutics Plc purchased 45,000 shares on May 16, 2016. The Insider buying transaction was reported by the company on May 18, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.53 per share for a total value of $68,700.00 , the company said in a SEC Form 4 Filing.
Adaptimmune Therapeutics PLC – ADR: On Thursday, May 19, 2016 heightened volatility was witnessed in Adaptimmune Therapeutics PLC – ADR which led to swings in the share price. The shares opened for trading at $9.39 and hit $9.76 on the upside , eventually ending the session at $9.55, with a gain of 2.47% or 0.23 points. The heightened volatility saw the trading volume jump to 1,77,249 shares. The 52-week high of the share price is $21.57 and the company has a market cap of $4,056,000 M . The 52-week low of the share price is at $6.19.
Company has been under the radar of several Street Analysts.Adaptimmune Therapeutics PLC – ADR is Initiated by Citigroup to Buy and the brokerage firm has set the Price Target at $15. The Rating was issued on Feb 25, 2016.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor platform. The Company has developed a platform that enables to identify cancer targets in the form of peptides which are short sequences of amino acids find and genetically engineer T-cell receptors (TCRs) and produce TCR therapeutic candidates for administration to patients. The Company’s target peptides are NY-ESO-1 and MAGE A-10. The Company’s affinity-enhanced TCR therapeutics targets the NY-ESO-1 or NY-ESO cancer antigen. The Company has completed the Phase I/II clinical trials for its NY-ESO TCR therapeutic candidate in patients with solid tumors and hematological malignancies including synovial sarcoma multiple myeloma melanoma ovarian cancer and esophageal cancer.